JP2018511628A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018511628A5 JP2018511628A5 JP2017553879A JP2017553879A JP2018511628A5 JP 2018511628 A5 JP2018511628 A5 JP 2018511628A5 JP 2017553879 A JP2017553879 A JP 2017553879A JP 2017553879 A JP2017553879 A JP 2017553879A JP 2018511628 A5 JP2018511628 A5 JP 2018511628A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- group
- alkyl
- formula
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 229910052799 carbon Inorganic materials 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 13
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- 150000001413 amino acids Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 9
- 235000018417 cysteine Nutrition 0.000 claims 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000005647 linker group Chemical group 0.000 claims 8
- 235000001014 amino acid Nutrition 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- 125000001544 thienyl group Chemical group 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 229940024606 amino acid Drugs 0.000 claims 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 4
- 125000005907 alkyl ester group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- -1 methoxy, pyridyl Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 108010016626 Dipeptides Proteins 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- IBAHLNWTOIHLKE-UHFFFAOYSA-N cyano cyanate Chemical compound N#COC#N IBAHLNWTOIHLKE-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 150000002825 nitriles Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 150000001945 cysteines Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 0 N=C(CC(CC1)=O)C1*1=CC=CC=CC1 Chemical compound N=C(CC(CC1)=O)C1*1=CC=CC=CC1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506393.6A GB201506393D0 (en) | 2015-04-15 | 2015-04-15 | Site-specific antibody-drug conjugates |
| GB1506393.6 | 2015-04-15 | ||
| PCT/EP2016/058371 WO2016166299A1 (en) | 2015-04-15 | 2016-04-15 | Site-specific antibody-drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018511628A JP2018511628A (ja) | 2018-04-26 |
| JP2018511628A5 true JP2018511628A5 (https=) | 2019-05-09 |
Family
ID=53333825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553879A Pending JP2018511628A (ja) | 2015-04-15 | 2016-04-15 | 部位特異的な抗体−薬物複合体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20180125994A1 (https=) |
| EP (1) | EP3283118A1 (https=) |
| JP (1) | JP2018511628A (https=) |
| KR (1) | KR20170137115A (https=) |
| CN (1) | CN107683146A (https=) |
| AU (1) | AU2016249877A1 (https=) |
| BR (1) | BR112017022256A2 (https=) |
| CA (1) | CA2981920A1 (https=) |
| GB (1) | GB201506393D0 (https=) |
| MX (1) | MX2017013154A (https=) |
| WO (1) | WO2016166299A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX375569B (es) | 2017-02-08 | 2025-03-04 | Adc Therapeutics Sa | Conjugados de pirrolobenzodiazepinas y anticuerpos |
| SI3579883T1 (sl) | 2017-02-08 | 2021-12-31 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| PT3612537T (pt) | 2017-04-18 | 2022-08-29 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina |
| AU2018253950A1 (en) | 2017-04-20 | 2019-09-19 | Adc Therapeutics Sa | Combination therapy with an anti-CD25 antibody-drug conjugate |
| WO2018193103A1 (en) * | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-psma antibody-drug conjugate |
| BR112019026498A2 (pt) | 2017-06-14 | 2020-07-14 | Adc Therapeutics Sa | regimes de dosagem para a administração de um adc anti-cd25 |
| DK3668874T3 (da) | 2017-08-18 | 2022-02-14 | Medimmune Ltd | Pyrrolobenzodiazepin-konjugater |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201820725D0 (en) | 2018-12-19 | 2019-01-30 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine resistance |
| US20220347309A1 (en) | 2018-12-19 | 2022-11-03 | Adc Therapeutics Sa | Pyrrolobenzodiazepine resistance |
| KR102890251B1 (ko) | 2019-03-15 | 2025-11-25 | 메드임뮨 리미티드 | 암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트 |
| HUE060364T2 (hu) * | 2019-03-29 | 2023-02-28 | Medimmune Ltd | Vegyületek és konjugátumaik |
| GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| TW202140076A (zh) * | 2020-01-22 | 2021-11-01 | 英商梅迪繆思有限公司 | 化合物及其軛合物 |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| MX2024002476A (es) * | 2021-08-27 | 2024-05-20 | Janssen Biotech Inc | Anticuerpos anti-psma y usos de estos. |
| CN116370651A (zh) * | 2023-04-04 | 2023-07-04 | 上海愿智生物技术有限公司 | 一种抗psma抗体-药物缀合物及其制备方法和应用 |
| TW202542201A (zh) * | 2023-12-29 | 2025-11-01 | 瑞士商T O A D 腫瘤學股份有限公司 | 抗psma軛合物及其使用方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20003099A3 (cs) * | 1998-02-25 | 2002-04-17 | Lexigen Pharmaceuticals Corporation | Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek |
| EP1817341A2 (en) * | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| JP5889181B2 (ja) * | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
| WO2012064733A2 (en) * | 2010-11-09 | 2012-05-18 | Medimmune, Llc | Antibody scaffold for homogenous conjugation |
| US10751346B2 (en) * | 2012-10-12 | 2020-08-25 | Medimmune Limited | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates |
| EP2906250B1 (en) * | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| PE20160209A1 (es) * | 2013-08-28 | 2016-05-09 | Stemcentrx Inc | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y metodos de uso |
-
2015
- 2015-04-15 GB GBGB1506393.6A patent/GB201506393D0/en not_active Ceased
-
2016
- 2016-04-15 AU AU2016249877A patent/AU2016249877A1/en not_active Abandoned
- 2016-04-15 MX MX2017013154A patent/MX2017013154A/es unknown
- 2016-04-15 JP JP2017553879A patent/JP2018511628A/ja active Pending
- 2016-04-15 CA CA2981920A patent/CA2981920A1/en not_active Abandoned
- 2016-04-15 CN CN201680022066.8A patent/CN107683146A/zh active Pending
- 2016-04-15 WO PCT/EP2016/058371 patent/WO2016166299A1/en not_active Ceased
- 2016-04-15 BR BR112017022256A patent/BR112017022256A2/pt not_active Application Discontinuation
- 2016-04-15 KR KR1020177030351A patent/KR20170137115A/ko not_active Withdrawn
- 2016-04-15 EP EP16716583.6A patent/EP3283118A1/en not_active Withdrawn
- 2016-04-15 US US15/566,411 patent/US20180125994A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018511628A5 (https=) | ||
| JP2018516243A5 (https=) | ||
| JP2018502902A5 (https=) | ||
| JP2020506951A5 (https=) | ||
| JP2020531471A5 (https=) | ||
| JP2016508130A5 (https=) | ||
| IL315310A (en) | Irak degraders and uses thereof | |
| RU2019122802A (ru) | Конъюганты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы | |
| JP2018516860A5 (https=) | ||
| RU2019138337A (ru) | Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии | |
| JP2019502650A5 (ja) | 抗ErbB2抗体−薬物コンジュゲート及びその組成物、そのための調製方法、並びにその使用 | |
| JP2020514419A5 (https=) | ||
| JP2014527974A5 (https=) | ||
| JP2021524449A5 (https=) | ||
| JP2016505586A5 (https=) | ||
| JP2014528466A5 (https=) | ||
| JP2014528467A5 (https=) | ||
| JP2017518040A5 (https=) | ||
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| JP2018070648A5 (https=) | ||
| JP2013505946A5 (https=) | ||
| JP2016531915A5 (https=) | ||
| JP2017506234A5 (https=) | ||
| JP2020519643A5 (https=) | ||
| JP2017528467A5 (https=) |